Okogen

Okogen is a private, clinical-stage biotech company innovating in the ophthalmic therapeutics space, specifically targeting the large and underserved market for acute infectious conjunctivitis. Its lead asset, OKG-0303, is a fixed-dose combination eye drop in Phase 2b development, aiming to be a 'one-stop-shop' treatment for all major infectious causes of pink eye. The company is led by a team with deep ophthalmic development experience and is positioned to address a significant unmet need, as there are currently no approved treatments for adenoviral conjunctivitis, which comprises over 90% of viral ocular infections.

Proprietary fixed-dose combination eye drop technology designed to treat both bacterial and viral pathogens causing conjunctivitis.

The competitive landscape is dominated by generic antibiotic eye drops, which are prescribed empirically but are ineffective against viral causes. There are no FDA-approved antiviral treatments for adenoviral conjunctivitis, making that segment non-competitive. Okogen's main competition would be other developers targeting the same unmet need, but its combination approach aims to differentiate by covering both bacterial and viral etiologies.